T cell gene therapy data

Preliminary results from the first part of a Phase I/II trial of T cell gene therapy showed no treatment-related safety problems, and that the genetically engineered cells persist for at least four weeks.

Escalating single doses of human T cells, genetically engineered with disease-specific receptors to recognize and destroy HIV-infected cells, were given to 29 patients. ...